Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast cancer.

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple
Negative and ER-positive, HER2-negative Breast Cancers